

Basis for the Amendment

The applicant has discovered a method for prevention and reversal of weight gain associated with the use of psychotropic active, antipsychotic or mood stabilizing drugs for the treatment of schizophrenia and other psychoses, bipolar disorders, depressive illness, impulse-control disorders and related conditions as well as the minimization of weight gain, through the concomitant use of histamine H₂-receptor antagonists. The combination use of a psychotropic active drug, such as nizatidine, famotidine, cimetidine, and ranitidine, with an histamine H₂-receptor antagonist, not only effectively treats the mental illness but surprisingly results in the prevention or reversal of weight gain associated with the conventional usage of these psychotropic, active antipsychotic or mood stabilizing drugs.

In order to emphasize the utilization of these two types of drugs in combination and the impact of the utilization of this combination of drugs on weight loss, each of the independent claims of the application have been amended to positively claim the use of a combination of two drugs, one a psychotropic active, antipsychotic or mood altering drug, designed for the treatment of particular mental illnesses including schizophrenia and other psychoses, bipolar disorders, depressive illness, impulse-control disorders and related conditions, and the second drug an histamine H₂-receptor antagonist to prevent or reverse weight gain normally

associated with taking the first drug. Basis for this amendment is contained on page 1, lines 5 - 7 and at a number of locations throughout the application, including the discussion of the psychotropic and mood altering drugs. No new subject matter is introduced by any of these amendments.

Analysis of Rejections

Rejections under 35 USC § 102

The USPTO asserts that U.S. Patent No. 4,293,562 ("Ritter") discloses all elements of the invention. As admitted by the USPTO, Ritter merely discloses the administration of an H₂-antagonists with an "anorexant" for the suppression of appetite of a mammal. As explained by Ritter, "anorexants" are nothing more than amphetamines or non-amphetamine compositions, which behave in a manner similar to amphetamines. (See Col. 1, lines 36 - 56.)

The applicant acknowledges that Ritter discloses the use of a particular H₂-antagonist, i.e., cimetidine. Further, the applicant acknowledges that the particular H₂-antagonist that is disclosed is utilized with the anorexant as a means to prevent weight gain. However, the applicant respectfully asserts that Ritter fails to disclose the second component of his claims i.e., the use of mood altering or psychotropic drugs especially for the treatment of schizophrenia and other psychoses, bipolar disorders, depressive illness, impulse-control disorders and related conditions. (The applicant notes that Claims 33 and 38 have not been rejected based on Ritter, presumably because these claims specifically claim particular antipsychotic drugs or mood altering drugs that are not disclosed by Ritter.)

The applicant respectfully asserts that there is no relationship between the use of an "anorexant," as taught by

Ritter, and the use of the "psychotropic" or mood altering drugs, that are claimed in the claims of the application. Ritter specifically defines an "anorexant" as being in the class defined in the Physicians' Desk Reference as an "appetite suppressant." (See Col.1, lines 36 - 43.) In contrast, the applicant is claiming the use of "antipsychotic" or "psychotropic" drugs, an entirely different class of drugs as listed in the same Physicians Desk References. (See pp 203 and 205, Ex. A.)

To emphasize this distinction, the applicants have amended the claims to clarify that the process requires the use of a psychotropic active compound or mood altering drug utilized for the treatment of very specific mental disorders, i.e. schizophrenia and other psychoses, bipolar disorders, depressive illness, impulse-control disorders and related conditions. These conditions are not the same as or in any way related to utilization of the drugs in Ritter for "suppressing the appetite impulse." (Col. 1, line 9) The entire focus of Ritter is on the "anorexic effects" from the use of a combination of amphetamines and cimetidine. (See the Title of the application, Col. 1, lines 9 - 10, 14 - 15, 19, Col. 2, lines 11 - 12, 22 - 23, 42 - 43, 52, 56, 62 and 67 and at other locations throughout the patent.) Not only does Ritter fail to disclose the use of an antipsychotic or psychotropic compound, as claimed, no person skilled in the art attempting to discover a drug combination to prevent weight gain and treat mental disorders including

schizophrenia and other psychoses, bipolar disorders, depressive illness, impulse-control disorders and related conditions utilizing an antipsychotic drug would look to the use of anorexants, as is taught by Ritter, as these drugs are not antipsychotic drugs. (See Exhibit A)

Further, there is no disclosure of any utilization of any psychotropic or mood altering drug for any use in Ritter, and specifically no disclosure of the use of these drugs for the treatment of various mental illnesses, as is now claimed in the application. Thus, each and every element of the invention, as claimed, is clearly not taught by Ritter, as Ritter fails to disclose the utilization of the particular psychotropic active drugs alone or for the treatment of various mental illnesses by use of these drugs, as is claimed in all the claims of the application.

In addition, from a medical prospective, the applicant asserts that it would be counterintuitive to utilize the amphetamines, that are disclosed in Ritter, for the treatment of psychoses of the type that are treated by the drugs claimed in the application. It is well known that individuals with these types of mental disorders have a much higher than average rate of substance abuse than the general population. Thus, they would not be a population well served by the use of amphetamines. In addition, bipolar patients can easily be pushed into mania by the addition of psycho stimulants, such as amphetamines. Further, while this patent has

been around for over twenty years, the applicant respectfully asserts that it has never been marketed. This would indicate to a person skilled in the art at the time of filing of the application that it lacks clinical usefulness.

Further, the use of the terms "mood altering drugs" or "psychotropic agents" indicates a drug that induces responses in a patient that are not induced by the utilization of anorexants. Further, these drugs are not utilized for the treatment of the specific mental disorders that are now claimed in all the independent claims of the application.

Finally, under any circumstances Claims 33 and 38 are clearly allowable over Ritter, as they claim the use of particular psychotropic or mood altering drugs, which are not disclosed or suggested by Ritter.

Rejection under 35 USC § 103

The second argument made by the USPTO is that all claims of the application must be rejected based on the combination of Bymaster, et. al. in view of Deutsch, et. al. and Kaminiski and Vivino.

The applicant respectfully asserts that the USPTO has failed to satisfy its burden to establish *prima facie* obviousness. To reject claims under 35 USC § 103, the USPTO is required to identify where in the cited references there is a motivating suggestion to

combine a psychotropic active compound, a mood altering drug or an unconventional antipsychotic drug, specifically for a patient in need of said active compound, which is utilized for the treatment of particular types of mental illness, with a histamine H₂-receptor antagonists to minimize weight gain. (Note that many of the claims are method claims, claiming a "method for minimizing weight gain.") The applicant respectfully asserts that such motivation is clearly not present in any of the references cited. In fact, it is the applicant's view that the Examiner inherently acknowledges that there is no statement in any of the references that the combination of these drugs would result in a minimization of weight gain, as required to prove *prima facie* obviousness.

In In re Jones, 958 Fed.2d 347, 21 USPQ2d 1941, 1944 (Fed. Cir. 1992), citing In re Lalu, 747 Fed2d 703, 705, 223 USPQ 1257, 1258 (Fed. Cir. 1984), the Court stated that "[t]he prior art must provide one of ordinary skill in the art the motivation to make the proposed... modification needed to arrive at the claim compound." The USPTO has failed to disclose any suggestion or motivation from any reference which would suggest the combination of a psychotropic, mood altering or antipsychotic drug for the treatment of particular types of mental illness to be utilized with a histamine H₂-receptor antagonist for a patient who also wishes to minimize weight gain from taking that drug.

Moreover, the USPTO has failed to prove that the combination

of these two types of drugs is a "desirable" modification to cause the minimization of weight gain. The "desirability" of the motivation must also be proved to establish *prima facie* obviousness.

The mere fact that the prior art may be modified in the manner suggested by the Examiner does not make modification obvious, unless the prior art suggested the desirability of the modification. In re Fritch, 922 Fed.2d 1260, 23 USPQ2d 1780, 1783-84 (Fed. Cir. 1992).

In addition, the USPTO has failed to show that the motivating suggestion to combine these two different types of drugs for patients in need of a mental illness drug, but who also wishes to minimize weight gain, is an "explicit" suggestion and not merely some vague reference to a possible modification.

...Invention can not be found obvious unless there was some explicit teaching or suggestion in art to motivate one of ordinary skill to combine elements so as to create same invention. Winner International Royalty Corp. vs. Wang, 48 USPQ2nd 1139, 1140 (D.C.D.C. 1998)

Clearly there is no teaching of a motivation within any of these references that it would be desirable to combine an effective mental illness drug with a histamine H₂-receptor to minimize weight gain, much less an explicit teaching of this result.

In support of its position, the USPTO asserts that Bymaster can be combined with one of the other references to teach the combination use of an antipsychotic drug with a histamine H₂-receptor for the control of weight gain in patients in need of the antipsychotic drug for the treatment of mental illness. While it

is important not to limit the analysis under § 103 to a reference-by-reference approach, it is necessary first to understand the teaching of the primary reference cited, Bymaster, et. al. before it can be determined whether that reference can be combined with any of the other cited references.

The teaching of Bymaster, et. al. is quite simple. It teaches that a patient suffering from various mental illnesses can be treated by "administrating to said patient an effective amount of a first component which is atypical antipsychotic, in combination with an effective amount of a second component which is a serotonin reuptake inhibitor." (Page 2, lines 17 - 19.)

The first component, which is an atypical antipsychotic, is one of the two components that are claimed by the applicant. However, the second component is not taught or suggested by the applicant in the application. The second component, as discussed throughout Bymaster, is a serotonin reuptake inhibitor. The list of serotonin reuptake inhibitors is contained on page 3 of Bymaster. The remaining pages of Bymaster discuss the combination of these two components. Each of the Examples as well as every claim discloses utilization of only these two components. Thus, the teaching of Bymaster is that if one wants to treat various psychoses, one should combine an atypical antipsychotic with a serotonin reuptake inhibitor. There is absolutely no teaching in Bymaster of the use of a histamine H₂-receptor antagonist, as is

claimed in the application. In fact, there is no suggestion or any motivation in Bymaster, et. al. for the use of an H₂-antagonist for any use! There is also no teaching that any of the disclosed products would be useful "to minimize weight gain." These facts are acknowledged by the USPTO on page 4 of its Office Action where it states "Bymaster does not teach the use of a H₂-antagonist in his methods." Any such motivation or suggestion must be provided by one of the other references that are cited. Thus, the issue is whether that motivation or suggestion is explicitly provided by any of the other references that are cited.

The first two references that are cited, Deutsch, et. al. and Kaminiski teach the addition of an H₂-antagonist solely for the treatment of schizophrenia. Neither Kaminiski nor Deutsch, et. al. teach the use of H₂-antagonists with psychotropic active, mood altering or unconventional antipsychotic drugs, as claimed by the applicant, for any use. Further, neither teach the use of H₂-antagonists to prevent weight gain.

The USPTO acknowledges that none of Bymaster, Deutsch or Kaminiski "explicitly recite that H₂-antagonist can also be used for purposes of weight control and weight loss." (Page 4.) Thus, the combination of these three references are acknowledged by the USPTO as not teaching what is claimed in any of the claims of the application. Thus, it is clear and is acknowledged by the USPTO that there is no motivation or suggestion provided in any of these

three references to combine the use of an H₂-receptor antagonist with an psychotropic or mood altering drug for the treatment of specific types of mental illness while also controlling weight gain.

The USPTO cites as the sole reference in support of its combination of references, Vivino, U.S. Patent No. 4,220,653. In the Office Action, the USPTO asserts that "Vivino describes the state of art that H₂-antagonist such as cimetidine are used for persons suffering from excessive weight as a mode to reduce the feelings of hunger and food intake. Thus, Vivino suggests that H₂-antagonists such as cimetidine are effective for suppressing appetite." The USPTO then concludes that, "[t]herefore, employing weight control benefits of H₂-antagonists as described by as described by Vivino would have also been obvious, because the ordinary skill in the art would have had a reasonable expectation of success to observe all therapeutic benefits of such drugs including its appetite reducing effects in the recipient patients."

(Page 5)

It is acknowledged that Vivino teaches the use of H₂-antagonist for excessive weight gain. However, that is not the issue. Further, it is clear that Vivino, by itself, fails to disclose the use of an H₂-antagonist with any of the antipsychotic drugs that are taught in the other references. Thus, the ultimate issue is whether there is a motivation to **combine** the teaching of

Vivino with the teachings of the other cited references to teach the invention, as claimed. Is there a suggestion or motivation from any of the cited references that the combination of the H₂-antagonist, taught by Vivino, would reduce weight gain in individuals taking antipsychotic drugs? The simple answer is "No." In fact, Vivino teaches away from this combination of these drugs. All that is necessary to understand what is taught by Vivino is to review the method of use of the H₂-antagonist according to the invention of Vivino, as disclosed at Col. 3 through Col. 4. Vivino states as follows,

The method according to the invention has been evaluated in forty-two cases which are summarized in the following table:

The last of the requirements for the Vivino method states as follows:

15. No patient was on any other medication.

Further, none of the individuals identified in Vivino had any mental health issues.

Thus, the clear and unambiguous teaching of Vivino is that the H₂-antagonist may only be utilized when no other drugs are also utilized which might interfere with the operation of the H₂-antagonists. While not stated directly, it is also clear that Vivino teaches that highly active and highly reactive drugs, such as the antipsychotic and mood altering drugs, should not be taken

at the same time as H₂-antagonist, if weight loss is to be achieved.


Further, applicant asserts that the method of Vivino has never been commercialized, as no H₂-antagonist has commercially been offered for weight loss. Thus, the industry has failed to accept the teaching of Vivino, perhaps because of the change in the understanding concerning the mechanism of weight loss since Vivino.

Thus, not only does Vivino not disclose the combination of H₂-antagonists with antipsychotic or mood altering drugs, as claimed in the application, it teaches away from the utilization of the H₂-antagonist with any drugs, including antipsychotic and mood altering drugs. Thus, not only is there no motivation to combine the teaching of Vivino with the teaching of the three other references, the teaching of Vivino is counter intuitive to that utilization. Under 35 USC § 103 to combine references, it is required that there be a motivation or suggestion in the references for that combination. Not only is that motivation and suggestion lacking, Vivino teaches away from such combination.

CONCLUSION

The applicant respectfully assert that there is no teaching in any of the references that are cited of a motivation to combine Vivino, which is the only reference teaching the utilization of H₂-antagonist for weight control, with any of the other cited references. Thus, the applicant respectfully asserts that all claims of the application are allowable over the references cited. If there are any questions concerning this Amendment, please contact applicant's counsel.

Respectfully submitted,



Scott R. Cox
Reg. No. 31,945
LYNCH, COX, GILMAN & MAHAN, P.S.C.
400 West Market Street, Suite 2200
Louisville, Kentucky 40202
(502) 589-4215

CERTIFICATE OF SERVICE

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 1, 2005 Nelly Hart

SRC:hh
C:\SRC\patent\p1109\P1109response020105.wpd
01-26-05\101171

PDR®
48
EDITION
1994

PHYSICIANS' DESK REFERENCE®

Medical Consultant

Ronald Arky, MD, Charles S. Davidson, Professor of Medicine and Master,
Francis Weld Peabody Society, Harvard Medical School

Product Manager: Stephen B. Greenberg

Sales Manager: James R. Pantaleo

Account Managers

Dik N. Barsamian
Jeffrey M. Keller
Michael S. Sarajian
Joanne C. Terzides

Commercial Sales Manager: Robin B. Bartlett

Direct Marketing Manager: Robert W. Chapman

Manager, Professional Data: Mukesh Mehta, RPh

Manager, Database Administration: Lynne Handler

Editor, Special Projects: David W. Sifton

Director of Production: Marjorie A. Duffy

Assistant Director of Production: Carrie Williams

Production Manager: Kimberly V. Hiller

Production Coordinator: Tara L. Walsh

Format Editor: Gregory J. Westley

Index Editor: Beverly Pfohl

Art Associate: Joan K. Akerlind

Manager, Electronic Prepress: Gregory J. Thomas

Digital Photography: Shawn W. Cahill



Copyright © 1994 and published by Medical Economics Data Production Company at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Nonprescription Drugs®, and PDR For Ophthalmology® are trademarks of Medical Economics Data Production Company, registered in the United States Patent and Trademark Office. PDR Guide to Drug Interactions • Side Effects • Indications™, The PDR® Family Guide to Prescription Drugs™, PDR® Library on CD-ROM™, PDR® Drug Interactions/Side Effects/Indications Diskettes™, and Pocket PDR™ are trademarks of Medical Economics Data Production Company.

Officers of Medical Economics Data Production Company: **President and Chief Executive Officer:** Norman R. Snesil; **Executive Vice President:** Mark L. Weinstein; **Senior Vice President and Chief Financial Officer:** J. Crispin Ashworth; **Senior Vice President of Operations:** Curtis B. Allen; **Vice President of Product Management:** William J. Gole; **Vice President of Sales:** Krystyna H. Gurstelle; **Vice President of Sales and Marketing:** Thomas F. Rice; **Vice President of Operations:** John R. Ware; **Vice President of Information Systems and Services:** Edward J. Zecchini; **Vice President of Business Development:** Raymond M. Zoeller

ISBN: 1-56363-061-3

BEST AVAILABLE COPY

Talacen (Sanofi Winthrop Pharmaceuticals).....	327, 2117	Marcaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2101	Hurricane Topical Anesthetic Liquid, .25 gm, 1 oz Wild Cherry and Pina Colada .25 ml Dry Handle Swab Wild Cherry, 1/4 oz Wild Cherry (Beutlich).....	607	Alka-Seltzer Effervescent Antacid and Pain Reliever (Miles Consumer).....	1563
Talwin Ampuls (Sanofi Winthrop Pharmaceuticals).....	2119	Nesacaine-MPF Injection (Astra).....	553	Hurricane Topical Anesthetic Spray Kit (Beutlich).....	607	Alka-Seltzer Extra Strength Effervescent Antacid and Pain Reliever (Miles Consumer).....	1565
Talwin Carpuject (Sanofi Winthrop Pharmaceuticals).....	2119	Sensorcaine with Epinephrine Injection (Astra).....	555			Alka-Seltzer (Flavored) Effervescent Antacid and Pain Reliever (Miles Consumer).....	1564
Talwin Compound (Sanofi Winthrop Pharmaceuticals).....	2120	Sensorcaine Injection (Astra).....	555	TOPICAL OPHTHALMIC (see OPHTHALMIC PREPARATIONS, ANESTHETICS)			
Talwin Injection (Sanofi Winthrop Pharmaceuticals).....	2119	Sensorcaine-MPF with Epinephrine Injection (Astra).....	555	ANGINAL PREPARATIONS (see CARDIOVASCULAR AGENTS: BETA BLOCKERS, CALCIUM CHANNEL BLOCKERS, & VASODILATORS, CORONARY)			
Talwin Nx (Sanofi Winthrop Pharmaceuticals).....	327, 2120	Xylocaine Injections (Astra).....	563				
Tylenol with Codeine Phosphate Oral Solution (McNeil Pharmaceutical).....	318, 1364	Xylocaine with Epinephrine Injections (Astra).....	563	ANORECTAL PRODUCTS			
Tylenol with Codeine Phosphate Tablets (McNeil Pharmaceutical).....	318, 1364	INHALATION		CREAMS, FOAMS, LOTIONS, OINTMENTS			
Tylox Capsules (McNeil Pharmaceutical).....	318, 1366	Fluothane (Wyeth-Ayerst).....	2534	Analpram-HC Rectal Cream 1% and 2.5% (Ferndale).....	920		
Vicodin (Knoll).....	313, 1143	Suprane (Anaquest).....	510	Anusol-HC Cream 2.5% (Parke-Davis).....	321, 322, 1718		
Vicodin ES Tablets (Knoll).....	313, 1144	INJECTABLE		Cortifoam (Reed & Carnrick).....	324, 1836		
Wygesic Tablets (Wyeth-Ayerst).....	337, 2627	Brevital Sodium (Lilly).....	1209	Epifoam (Reed & Carnrick).....	324, 1838		
Zydore Capsules (Du Pont Pharma Multi-Source Products).....	893	Carbocaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2088	Hurricane Topical Anesthetic Gel, 1 oz Wild Cherry, Pina Colada, Watermelon, 1/4 oz Wild Cherry (Beutlich).....	607		
NEURALEPTANALGESIA		Diprivan Injection (Stuart).....	332, 2328	Hurricane Topical Anesthetic Liquid, .25 gm, 1 oz Wild Cherry and Pina Colada .25 ml Dry Handle Swab Wild Cherry, 1/4 oz Wild Cherry (Beutlich).....	607		
Inapsine Injection (Janssen).....	312, 1091	Duranest Injections (Astra).....	541	Nupercainal Cream and Ointment (Ciba Pharmaceutical).....	832		
Innovar Injection (Janssen).....	312, 1092	Marcaine Hydrochloride with Epinephrine 1:200,000 (Sanofi Winthrop Pharmaceuticals).....	2101	Pazo Hemorrhoid Ointment & Suppositories (Bristol-Myers Products).....	684		
NON-NARCOTIC & ANXIOLYTIC		Marcaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2101	Wyanoils Relief Factor Hemorrhoidal Suppositories (Wyeth-Ayerst).....	337, 2623		
Axotal (Savage).....	327, 2123	Nesacaine Injections (Astra).....	553	SUPPOSITORIES			
Esigic-Plus Tablets (Forest Pharmaceuticals).....	309, 954	Nesacaine-MPF Injection (Astra).....	553	Anusol-HC Suppositories (Parke-Davis).....	321, 1719		
Floricef Tablets (Sandoz Pharmaceuticals).....	327, 2050	Sarapin (High Chemical).....	1035	Nupercainal Suppositories (Ciba Pharmaceutical).....	832		
Florinal Capsules (Sandoz Pharmaceuticals).....	327, 2052	Sensorcaine with Epinephrine Injection (Astra).....	555	OTHER			
Florinal Tablets (Sandoz Pharmaceuticals).....	327, 2052	Sensorcaine Injection (Astra).....	555	Hurricane Topical Anesthetic Aerosol Spray, 2 oz (wild cherry flavor) (Beutlich).....	607		
Phrenilin Forte Capsules (Carnrick).....	307, 782	Sensorcaine-MPF with Epinephrine Injection (Astra).....	555	Hurricane Topical Anesthetic Spray Kit (Beutlich).....	607		
Phrenilin Tablets (Carnrick).....	307, 782	Versed Injection (Roche Laboratories).....	1956	ANOREXIANTS/SYPATHOMIMETICS (see APPETITE SUPPRESSANTS)			
Sedapap Tablets 50 mg/650 mg (Mayrand Pharmaceuticals).....	1333	Xylocaine Injections (Astra).....	563	ANTACIDS & ANTIFLATULENTS			
OTHER SALICYLATES & COMBINATIONS		Xylocaine with Epinephrine Injections (Astra).....	563	ALUMINUM ANTACIDS			
Mono-Gesic Tablets (Central Pharmaceuticals).....	307, 790	LOCAL		AlternaGEL Liquid (J&J-Merck Consumer).....	312, 1107		
No-Dolo (Clint Pharmaceuticals).....	839	Carbocaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2088	Alu-Cap Capsules (3M Pharmaceuticals).....	1274		
Salflex Tablets (Carnrick).....	307, 783	Marcaine Hydrochloride with Epinephrine 1:200,000 (Sanofi Winthrop Pharmaceuticals).....	2101	Alu-Tab Tablets (3M Pharmaceuticals).....	1274		
Trilisate Liquid (Purdue Frederick).....	1828	Marcaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2101	Amphojel Suspension (Wyeth-Ayerst).....	2511		
Trilisate Tablets (Purdue Frederick).....	323, 1828	RECTAL		Amphojel Suspension without Flavor (Wyeth-Ayerst).....	2511		
TOPICAL ANALGESIC		Nupercainal Cream and Ointment (Ciba Pharmaceutical).....	832	Amphojel Tablets (Wyeth-Ayerst).....	2511		
Dyclone 0.5% and 1% Topical Solutions, USP (Astra).....	543	RETROBULAR		Basaljel Capsules (Wyeth-Ayerst).....	2520		
Thera-Gesic (Mission).....	1616	Duranest Injections (Astra).....	541	Basaljel Suspension (Wyeth-Ayerst).....	2520		
Zostrix (GenDerm).....	999	Marcaine Hydrochloride with Epinephrine 1:200,000 (Sanofi Winthrop Pharmaceuticals).....	2101	Basaljel Tablets (Wyeth-Ayerst).....	2520		
Zostrix-HP Topical Analgesic Cream (GenDerm).....	999	Marcaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2101	ANTACID/ANTIFLATULENT COMBINATIONS			
TOPICAL COUNTERIRRITANT		SPINAL		Citra pH (ValMed).....	2466		
Thera-Gesic (Mission).....	1616	Marcaine Spinal (Sanofi Winthrop Pharmaceuticals).....	2104	Maalox Antacid Plus Anti-Gas (Rhône-Poulenc Rorer Consumer).....	1867		
Therapeutic Mineral Ice, Pain Relieving Gel (Bristol-Myers Products).....	306, 684	Novocain Hydrochloride for Spinal Anesthesia (Sanofi Winthrop Pharmaceuticals).....	2111	Extra Strength Maalox Antacid Plus Anti-Gas Suspension (Rhône-Poulenc Rorer Consumer).....	1867		
OTHER		Pontocaine Hydrochloride for Spinal Anesthesia (Sanofi Winthrop Pharmaceuticals).....	2115	Extra Strength Maalox Antacid Plus Anti-Gas Tablets (Rhône-Poulenc Rorer Consumer).....	1867		
Dolobid Tablets (Merck & Co., Inc.).....	319, 1449	TOPICAL		Mynta Liquid (J&J-Merck Consumer).....	312, 1108		
Levoprome (Immunex).....	1071	Americaine Anesthetic Lubricant (Pisons Pharmaceuticals).....	925	Mynta Tablets (J&J-Merck Consumer).....	312, 1108		
Norflex Injection (3M Pharmaceuticals).....	316, 1281	Americaine Otic Topical Anesthetic Ear Drops (Pisons Pharmaceuticals).....	926	Mynta Double Strength Tablets (J&J-Merck Consumer).....	312, 1108		
Norflex Sustained-Release Tablets (3M Pharmaceuticals).....	316, 1281	Analpram-HC Rectal Cream 1% and 2.5% (Ferndale).....	920	ANTIFLATULENTS			
Parafon Forte DSC Caplets (McNeil Pharmaceutical).....	318, 1362	Anestacon Jelly (Webcon).....	2486	Charcoal Plus Tablets (Kramer).....	1146		
Sarapin (High Chemical).....	1035	Cetacaine Topical Anesthetic (Cetylite).....	804	Flatulex Tablets (Dayton).....	862		
ANEMIA PREPARATIONS (see HEMATINICS)		Cocaine Hydrochloride Topical Solution (Astra).....	537	Infants' Mylicon Drops (J&J-Merck Consumer).....	312, 1108		
ANESTHETICS		Emia Cream (Astra).....	544	Mynta Gas Tablets-40 mg (J&J-Merck Consumer).....	312, 1109		
CAUDAL		Epifoam (Reed & Carnrick).....	324, 1838	Mynta Gas Tablets-80 mg (J&J-Merck Consumer).....	312, 1109		
Carbocaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2088	Ethyl Chloride, U.S.P. (Gebauer).....	979	COMBINATION ANTACIDS			
Duranest Injections (Astra).....	541	Fluoro-Methane (Gebauer).....	980	Alka-Seltzer Effervescent Antacid (Miles Consumer).....	1565		
Marcaine Hydrochloride with Epinephrine 1:200,000 (Sanofi Winthrop Pharmaceuticals).....	2101	Fluro-Ethyl (Gebauer).....	980				
Marcaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2101	Nupercainal Cream and Ointment (Ciba Pharmaceutical).....	832				
Nesacaine-MPF Injection (Astra).....	553	Oratect Gel (MGI Pharma).....	1274				
Sensorcaine with Epinephrine Injection (Astra).....	555	Prasomone Cream, Lotion & Ointment (Ferndale).....	922				
Sensorcaine Injection (Astra).....	555	ProctoCream-HC (Reed & Carnrick).....	324, 1841				
Sensorcaine-MPF with Epinephrine Injection (Astra).....	555	Proctofoam-HC (Reed & Carnrick).....	324, 1842				
Xylocaine Injections (Astra).....	563	TOPICAL & MUCOSAL					
Xylocaine with Epinephrine Injections (Astra).....	563	Hurricane Topical Anesthetic Aerosol Spray, 2 oz (wild cherry flavor) (Beutlich).....	607				
EPIDURAL		Hurricane Topical Anesthetic Gel, 1 oz Wild Cherry, Pina Colada, Watermelon, 1/4 oz Wild Cherry (Beutlich).....	607				
Carbocaine Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2088						
Duranest Injections (Astra).....	541						
Marcaine Hydrochloride with Epinephrine 1:200,000 (Sanofi Winthrop Pharmaceuticals).....	2101						

Nuprin Ibuprofen/Analgesic Tablets & Caplets (Bristol-Myers Products).....	306, 684	Vancenase Pocket-Haler Nasal Inhaler (Schering).....	328, 2174	Neosar (Adria).....	465	Mintezol Suspension (Merck & Co., Inc.).....	1495
Orudis Capsules (Wyeth-Ayerst).....	336, 2571	Vancereil Inhaler (Schering).....	328, 2176	NEOSAR Lyophilized (Adria).....	2640	Vermox Chewable Tablets (Janssen).....	312, 1103
Ponstel (Parke-Davis).....	322, 1768	V6Sol HC Otic Solution (Wallace).....	2484	Novantrone for Injection Concentrate (Immunex).....	1076	STRONGYLOIDS (THREADWORM)	
Relafen Tablets (SmithKline Beecham Pharmaceuticals).....	330, 2275	OTHER		Paraplatin for Injection (Bristol-Myers Oncology).....	306, 662	Mintezol Chewable Tablets (Merck & Co., Inc.).....	319, 1495
Tolectin (200, 400 and 600 mg) (McNeil Pharmaceuticals).....	318, 1363	Kutapressin Injection (Schwarz Pharma).....	2180	Platinol (Bristol-Myers Oncology).....	666	Mintezol Suspension (Merck & Co., Inc.).....	1495
Toradol IM Injection (Syntex).....	333, 2372	Plaquenil Sulfate Tablets (Sanofi Winthrop Pharmaceuticals).....	327, 2113	Platinol-AQ Injection (Bristol-Myers Oncology).....	306, 668	TAENIA (TAPEWORM)	
Toradol Oral (Syntex).....	333, 2372	ANTILPEDEMIC (see HYPOLIPIDEMICS)		Roferon-A Injection (Roche Laboratories).....	1947	Atabrine Hydrochloride Tablets (Sanofi Winthrop Pharmaceuticals).....	2087
Voltaren Tablets (Geigy).....	309, 996	ANTIMETABOLITES (see ANTINEOPLASTICS)		Taxol (Bristol-Myers Oncology).....	306, 670	Niclocide Chewable Tablets (Miles Pharmaceutical).....	320, 1588
SALICYLATES		ANTIMETAL POISONING (see ANTIDOTES)		Vumon (Bristol-Myers Oncology).....	674	TREMATODES (SCHISTOSOMES)	
Asacol Delayed-Release Tablets (Procter & Gamble Pharmaceuticals).....	323, 1805	ANTIMYCOTICS (see FUNGAL MEDICATIONS)		Zanosar Sterile Powder (Upjohn).....	2459	Bitricide Tablets (Miles Pharmaceutical).....	320, 1570
Disalcid Capsules (3M Pharmaceuticals).....	315, 1276	ANTINEOPLASTICS		HORMONES		TRICHURIS (WHIPWORM)	
Disalcid Tablets (3M Pharmaceuticals).....	315, 1276	ADJUNCT		Depo-Provera (Upjohn).....	2417	Mintezol Chewable Tablets (Merck & Co., Inc.).....	319, 1495
Dolobid Tablets (Merck & Co., Inc.).....	319, 1449	Ergamisol Tablets (Janssen).....	312, 1087	Emcynt Capsules (Kabi Pharmacia).....	313, 1113	Mintezol Suspension (Merck & Co., Inc.).....	1495
Mono-Gesic Tablets (Central Pharmaceuticals).....	307, 790	Garite Injection (Fujisawa).....	968	Estrace (Mead Johnson Laboratories).....	318, 1369	Vermox Chewable Tablets (Janssen).....	312, 1103
Pentasa (Marion Merrell Dow).....	316, 1315	Leukine for IV Infusion (Immunex).....	1068	Lupron Depot 7.5 mg (TAP Pharmaceuticals).....	333, 2385	PROTOZOA	
Rowasa Rectal Suppositories, 500 mg (Solvay).....	2307	Neupogen for Injection (Amgen).....	304, 504	Lupron Injection (TAP Pharmaceuticals).....	2381	AMEBAS, EXTRAEINTESTINAL	
Rowasa Rectal Suspension Enema 4.0 grams/unit (60 mL) (Solvay).....	331, 2307	Zofran Injection (Cerenex).....	308, 795	Megace Tablets (Bristol-Myers Oncology).....	306, 659	Aralen Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2085
Salflex Tablets (Carnrick).....	307, 783	Zofran Tablets (Cerenex).....	308, 797	Sandostatin Injection (Sandoz Pharmaceuticals).....	327, 2077	Aralen Phosphate Tablets (Sanofi Winthrop Pharmaceuticals).....	327, 2086
Trilisate Liquid (Purdue Frederick).....	1828	ANDROGEN INHIBITOR		Stilphostrol Tablets and Ampuls (Miles Pharmaceutical).....	320, 1591	Flagyl Tablets (Searle).....	329, 2208
Trilisate Tablets (Purdue Frederick).....	323, 1828	Eulexin Capsules (Schering).....	328, 2138	TACE 12 mg Capsules (Marion Merrell Dow).....	317, 1326	Protostat Tablets (Ortho Pharmaceutical).....	321, 1704
STEROIDS & COMBINATIONS		Lupron Depot 7.5 mg (TAP Pharmaceuticals).....	333, 2385	TACE 25 mg Capsules (Marion Merrell Dow).....	317, 1326	AMEBAS, INTESTINAL	
AeroBid Inhaler System (Forest Pharmaceuticals).....	309, 948	Lupron Injection (TAP Pharmaceuticals).....	2381	Teslac (Bristol-Myers Oncology).....	672	Flagyl Tablets (Searle).....	329, 2208
AeroBid-M Inhaler System (Forest Pharmaceuticals).....	309, 948	ANTIBIOTIC DERIVATIVES		Zoladex (ZENECA PHARMACEUTICALS).....	337, 2638	Protostat Tablets (Ortho Pharmaceutical).....	321, 1704
Aristocort Suspension (Forte Parenteral) (Fujisawa).....	959	Adriamycin PFS (Adria).....	458	IMMUNOMODULATORS		Yodoxin (Glenwood).....	1025
Aristocort Suspension (Intralesional) (Fujisawa).....	959	Adriamycin RDF (Adria).....	459	Proleukin for Injection (Cetus Oncology).....	801	GIARDIAS	
Aristospan Suspension (Intra-articular) (Fujisawa).....	962	Blenoxane (Bristol-Myers Oncology).....	653	Alkeran for Injection (Burroughs Wellcome).....	686	Atabrine Hydrochloride Tablets (Sanofi Winthrop Pharmaceuticals).....	2087
Aristospan Suspension (Intralesional) (Fujisawa).....	962	Cerubidine (Wyeth-Ayerst).....	2526	Alkeran Tablets (Burroughs Wellcome).....	306, 688	MALARIA	
Azmacor Oral Inhaler (Rhône-Poulenc Rorer Pharmaceuticals Inc.).....	324, 1845	Cosmegen Injection (Merck & Co., Inc.).....	1423	Emcynt Capsules (Kabi Pharmacia).....	313, 1113	Aralen Hydrochloride Injection (Sanofi Winthrop Pharmaceuticals).....	2085
Beclivent Inhalation Aerosol and Refill (Allen & Hanburys).....	303, 474	Doxorubicin Hydrochloride for Injection, USP (Astra).....	539	Leukeran Tablets (Burroughs Wellcome).....	307, 722	Aralen Phosphate Tablets (Sanofi Winthrop Pharmaceuticals).....	327, 2086
Beconase AQ Nasal Spray (Allen & Hanburys).....	304, 475	Doxorubicin Hydrochloride for Injection, USP (Cetus Oncology).....	799	Mustargen (Merck & Co., Inc.).....	1500	Atabrine Hydrochloride Tablets (Sanofi Winthrop Pharmaceuticals).....	2087
Beconase Inhalation Aerosol & Refill (Allen & Hanburys).....	303, 304, 475	Doxorubicin Hydrochloride Injection, USP (Cetus Oncology).....	799	Thiotape (Immunex).....	415, 1078	Daraprim Tablets (Burroughs Wellcome).....	306, 695
Celestone Soluspan Suspension (Schering).....	2130	Idamycin for Injection (Adria).....	461	STERIODS & COMBINATIONS		Fansidar Tablets (Roche Laboratories).....	325, 1923
Cortene (Solvay).....	2298	ANTIESTROGEN		Celestone Soluspan Suspension (Schering).....	2130	Lariam Tablets (Roche Laboratories).....	326, 1937
Cortifoam (Reed & Carnrick).....	324, 1836	Nolvadex Tablets (ZENECA PHARMACEUTICALS).....	337, 2630	OTHER		Plaquenil Sulfate Tablets (Sanofi Winthrop Pharmaceuticals).....	327, 2113
Cortone Acetate Sterile Suspension (Merck & Co., Inc.).....	1420	ANTIMETABOLITES		DTIC-Dome (Miles Pharmaceutical).....	1579	TOXOPLASMA	
Cortone Acetate Tablets (Merck & Co., Inc.).....	319, 1421	Cerubidine (Wyeth-Ayerst).....	2526	Elisar (Merck & Co., Inc.).....	1453	Daraprim Tablets (Burroughs Wellcome).....	306, 695
Decadron Elixir (Merck & Co., Inc.).....	1428	Efudex Cream (Roche Dermatologics).....	1907	Leucovorin Calcium for Injection (Immunex).....	1065	Fansidar Tablets (Roche Laboratories).....	325, 1923
Decadron Phosphate Injection (Merck & Co., Inc.).....	1431	Efudex Solutions (Roche Dermatologics).....	1907	Leucovorin Calcium Tablets (Immunex).....	1067	Lariam Tablets (Roche Laboratories).....	326, 1937
Decadron Phosphate Respihaler (Merck & Co., Inc.).....	1437	Fludara for Injection (Berlex Laboratories).....	304	Leustatin (Ortho Biotech).....	1651	Plaquenil Sulfate Tablets (Sanofi Winthrop Pharmaceuticals).....	327, 2113
Decadron Phosphate Turbinaire (Merck & Co., Inc.).....	1439	Fluorouracil Injection (Roche Laboratories).....	1924	Lysodren (Bristol-Myers Oncology).....	658	TRICHOMONAS	
Decadron Phosphate with Xyllocaine Injection, Sterile (Merck & Co., Inc.).....	1434	Intron A (Schering).....	2147	Oncovin Solution Vials & Hyporets (Lilly).....	1253	Flagyl Tablets (Searle).....	329, 2208
Decadron Tablets (Merck & Co., Inc.).....	319, 1429	Methotrexate Sodium Tablets, for Injection and LPF Injection (Immunex).....	1072	TheraCys BCG Live (Intravesical) (Connaught).....	854	Protostat Tablets (Ortho Pharmaceutical).....	321, 1704
Decadron-LA Sterile Suspension (Merck & Co., Inc.).....	1441	Mithracin (Miles Pharmaceutical).....	1585	Velban (Lilly).....	1268	ANTIPERSPIRANTS (see DEODORANTS & DERMATOLOGICALS, ANTIPERSPIRANTS)	
Deltasone Tablets (Upjohn).....	333, 2407	Nipent for Injection (Parke-Davis).....	322, 1762	VePesid Capsules and Injection (Bristol-Myers Oncology).....	306, 673	ANTIPSYCHOTIC MEDICATIONS (see PSYCHOTROPICS)	
Depo-Medrol Single-Dose Vial (Upjohn).....	2412	Purinethol Tablets (Burroughs Wellcome).....	307, 740	ANTIOXIDANTS		ANTIPYRETICS	
Depo-Medrol Sterile Aqueous Suspension (Upjohn).....	333, 2409	Roferon-A Injection (Roche Laboratories).....	1947	Protegra Vitamin & Mineral Supplement (Lederle).....	314, 1185	Arthritis Pain Ascriptin (Rhône-Poulenc Rorer Consumer).....	1866
Epifoam (Reed & Carnrick).....	324, 1838	Thioguanine Tablets, Tabloid Brand (Burroughs Wellcome).....	307, 756	ANTIPARASITICS		Regular Strength Ascriptin Tablets (Rhône-Poulenc Rorer Consumer).....	1866
Hydeltrol Injection, Sterile (Merck & Co., Inc.).....	1460	CYTOTOXIC AGENTS		ARTHROPODS		Feverall Infant's Suppositories (Upsher-Smith).....	2463
Hydeltrol-T.B.A. Sterile Suspension (Merck & Co., Inc.).....	1462	Adriamycin PFS (Adria).....	458	LICE		Feverall Junior Strength Suppositories (Upsher-Smith).....	2463
Hydrocortone Acetate Sterile Suspension (Merck & Co., Inc.).....	1463	Adriamycin RDF (Adria).....	459	A-200 Lice Control Spray and Kit (SmithKline Beecham).....	329, 2228	FEVERALL Sprinkle Caps Powder (Upsher-Smith).....	2463
Hydrocortone Phosphate Injection, Sterile (Merck & Co., Inc.).....	1465	BiCNU (Bristol-Myers Oncology).....	651	A-200, Pediculicide Shampoo Concentrate (SmithKline Beecham).....	329, 2229	Children's Motrin Ibuprofen Suspension (McNeil Consumer).....	317, 1335
Hydrocortone Tablets (Merck & Co., Inc.).....	319, 1467	CeeNU (Bristol-Myers Oncology).....	654	Rid Lice Control Spray (Pfizer Consumer Health Care).....	1779	Trilisate Liquid (Purdue Frederick).....	1828
Medrol Dosepak Unit of Use (Upjohn).....	333, 2431	Cerubidine (Wyeth-Ayerst).....	2526	Rid Lice Killing Shampoo (Pfizer Consumer Health Care).....	1779	Trilisate Tablets (Purdue Frederick).....	323, 1828
Medrol Tablets (Upjohn).....	333, 2431	Cytosar-U Sterile Powder (Upjohn).....	2405	SCABIES		Tylenol acetaminophen Children's Chewable Tablets & Elixir (McNeil Consumer).....	317, 1339
Nasacort Nasal Inhaler (Rhône-Poulenc Rorer Pharmaceuticals Inc.).....	324, 1856	Cytoxan for Injection (Bristol-Myers Oncology).....	306, 655	Elimite (permethrin) 5% Cream (Allergan Herber).....	485	Tylenol acetaminophen Children's Suspension Liquid (McNeil Consumer).....	1339
ProctoCream-HC (Reed & Carnrick).....	324, 1841	Cytoxan Tablets (Bristol-Myers Oncology).....	306, 655	Eurax Cream & Lotion (Westwood-Squibb).....	2491	Tylenol, Extra Strength, acetaminophen Adult Liquid Pain Reliever (McNeil Consumer).....	1341
Proctofoam-HC (Reed & Carnrick).....	324, 1842	Doxorubicin Hydrochloride for Injection, USP (Astra).....	539	HELMINTHS		Tylenol, Extra Strength, acetaminophen Gelscaps, Gelscaps, Caplets, Tablets (McNeil Consumer).....	317, 1340
Solu-Cortef Sterile Powder (Upjohn).....	2447	Doxorubicin Hydrochloride for Injection, USP (Cetus Oncology).....	799	ASCARIS (ROUNDWORM)			
Solu-Medrol Sterile Powder (Upjohn).....	334, 2449	Doxorubicin Hydrochloride Injection, USP (Cetus Oncology).....	799	Mintezol Chewable Tablets (Merck & Co., Inc.).....	319, 1495		
Vancenase AQ Nasal Spray 0.042% (Schering).....	328, 2175	Emcynt Capsules (Kabi Pharmacia).....	313, 1113	Mintezol Suspension (Merck & Co., Inc.).....	1495		
		Hexalen Capsules (U.S. Bioscience).....	333, 2390	Vermox Chewable Tablets (Janssen).....	312, 1103		
		Hydrea Capsules (Immunex).....	1064	ENTEROBIUS (PINWORM)			
		IFEX (Bristol-Myers Oncology).....	306, 657	Mintezol Chewable Tablets (Merck & Co., Inc.).....	319, 1495		
		Intron A (Schering).....	2147	Mintezol Suspension (Merck & Co., Inc.).....	1495		
		Matulane Capsules (Roche Laboratories).....	326, 1941	Vermox Chewable Tablets (Janssen).....	312, 1103		
		Mutamycin (Bristol-Myers Oncology).....	306, 661	HOOKWORM			
		Myleran Tablets (Burroughs Wellcome).....	307, 731	Mintezol Chewable Tablets (Merck & Co., Inc.).....	319, 1495		